Background and Expertise - The analyst holds a PhD in biochemistry and has extensive experience in analyzing clinical trials and biotech companies [1] - The analyst is passionate about educating investors on the science behind biotech investments and aims to help them conduct thorough due diligence [1] Disclosure and Independence - The analyst has no stock, option, or derivative positions in any mentioned companies and no plans to initiate such positions within the next 72 hours [2] - The article represents the analyst's own opinions and is not influenced by any compensation or business relationships with mentioned companies [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------------------------------------------------------------------------|----------------------------------------------| | | | | F ...

Exhibit 99.1 Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient selection (p = 0.009) from ongoing ACR-368 registrationalintent Phase 2b endometrial cancer study presented at ESMO - Endometrial cancer, a tumor type identified by AP3 as particularly sensitive to ACR-368 treatment, represents the first potential approval opportunit ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Acrivon Therapeutics, Inc. (ACRV) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Acrivon Therapeutics, Inc. is one of 1019 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector R ...

Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights WATERTOWN, Massachusetts, August 13, 2024 – Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Precision Predictive Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today reported fi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-41551 Acrivon Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Dela ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Acrivon Therapeutics, Inc. (ACRV) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Acrivon Therapeutics, Inc. is one of 1042 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Acrivon Therapeutics, Inc. (ACRV) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Acrivon Therapeutics, Inc. is a member of our Medical group, which includes 1045 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank ...

Acrivon Therapeutics (ACRV) is a precision oncology company that has seen significant progress across its proprietary Acrivon Predictive Precision Proteomics (AP3) platform in 2024.Acrivon Therapeutics achieved statistically significant prospective validation of its AP3 patient selection approach via its ACR-368 OncoSignature assay. This assay demonstrated an ability to identify ovarian and endometrial patients sensitive to ACR-368 monotherapy.Its lead pipeline candidate, ACR-368/prexasertib, a CHK1/2 inhib ...

The Zacks Medical-Drugs industry recovered from 2023 lows in early 2024 amid a slew of takeover deals. However, it slowed down thereafter, mostly due to macroeconomic pressure. Concerns around the economy and inflation, regular pipeline setbacks, uncertainty about the impact of Medicare drug price negotiations and the Federal Trade Commission’s scrutiny of M&A deals are some of the headwinds faced by drug/biotech companies. However, the industry has shown signs of a comeback in May. M&A activity remains str ...